Impairments in mitochondrial palmitoyl-CoA respiratory kinetics that precede development of diabetic cardiomyopathy are prevented by resveratrol in ZDF rats

Journal of Physiology

Volumn 592, Issue 12, 2014, Pages 2519-2533

  Beaudoin, Marie Soleil ^a   Perry, Christopher G R ^b   Arkell, Alicia M ^a   Chabowski, Adrian ^c   Simpson, Jeremy A ^a   Wright, David C ^a   Holloway, Graham P ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b YORK UNIVERSITY   (Canada)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; CERAMIDE; DIACYLGLYCEROL; GLUCOSE; PALMITOYL COENZYME A; PYRUVIC ACID; REACTIVE OXYGEN METABOLITE; RESVERATROL; TRIACYLGLYCEROL; CARDIOTONIC AGENT; GLUTATHIONE; GLUTATHIONE DISULFIDE; MULTIENZYME COMPLEX; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOENERGY; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DIET SUPPLEMENTATION; DIET THERAPY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; LIPID DIET; LIPID STORAGE; MALE; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL RESPIRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; TREATMENT OUTCOME; ANIMAL; DIABETIC CARDIOMYOPATHIES; DRUG EFFECTS; FIBROSIS; HEART LEFT VENTRICLE FUNCTION; HEART MITOCHONDRION; HEART VENTRICLE; KINETICS; LIPID METABOLISM; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; ZUCKER RAT;

ANIMALS; CARDIOTONIC AGENTS; DIABETIC CARDIOMYOPATHIES; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; FIBROSIS; GLUTATHIONE; GLUTATHIONE DISULFIDE; HEART VENTRICLES; KINETICS; LIPID METABOLISM; MALE; MITOCHONDRIA, HEART; PALMITOYL COENZYME A; RATS, ZUCKER; STILBENES; VENTRICULAR FUNCTION, LEFT;

EID: 84902345161     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2013.270538     Document Type: Article

References (58)

1. Abozguia K, Elliott P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I, Maher AR, Kaur K, Taylor J, Henning A, Ashrafian H, Watkins H & Frenneaux M (2010). Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122, 1562-1569.
2. Aliev M, Guzun R, Karu-Varikmaa M, Kaambre T, Wallimann T & Saks V (2011). Molecular system bioenergics of the heart: experimental studies of metabolic compartmentation and energy fluxes versus computer modeling. Int J Mol Sci 12, 9296-9331.
3. Anderson EJ, Kypson AP, Rodriguez E, Anderson CA, Lehr EJ & Neufer PD (2009a). Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol 54, 1891-1898.
4. 2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 119, 573-581.
5. Augustus AS, Buchanan J, Park TS, Hirata K, Noh HL, Sun J, Homma S, D'Armiento J, Abel ED & Goldberg IJ (2006). Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J Biol Chem 281, 8716-8723.
6. Baynes J & Murray DB (2009). Cardiac and renal function are progressively impaired with aging in Zucker diabetic fatty type II diabetic rats. Oxid Med Cell Longev 2, 328-334.
7. Beaudoin MS, Snook LA, Arkell AM, Simpson JA, Holloway GP & Wright DC (2013). Resveratrol supplementation improves white adipose tissue function in a depot-specific manner in Zucker diabetic fatty rats. Am J Physiol Regul Integr Comp Physiol 305, R542-R551.
8. Belke DD, Larsen TS, Gibbs EM & Severson DL (2000). Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 279, E1104-E1113.
9. Bonen A, Holloway GP, Tandon NN, Han XX, McFarlan J, Glatz JF & Luiken JJ (2009). Cardiac and skeletal muscle fatty acid transport and transporters and triacylglycerol and fatty acid oxidation in lean and Zucker diabetic fatty rats. Am J Physiol Regul Integr Comp Physiol 297, R1202-R1212.
10. Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX, Aziz S, Johnson JI, Bugger H, Zaha VG & Abel ED (2007). Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 56, 2457-2466.
11. Bugger H, Chen D, Riehle C, Soto J, Theobald HA, Hu XX, Ganesan B, Weimer BC & Abel ED (2009). Tissue-specific remodeling of the mitochondrial proteome in type 1 diabetic Akita mice. Diabetes 58, 1986-1997.
12. Chandler MP, Chavez PN, McElfresh TA, Huang H, Harmon CS & Stanley WC (2003). Partial inhibition of fatty acid oxidation increases regional contractile power and efficiency during demand-induced ischemia. Cardiovasc Res 59, 143-151.
13. Chen YR, Yi FF, Li XY, Wang CY, Chen L, Yang XC, Su PX & Cai J (2008). Resveratrol attenuates ventricular arrhythmias and improves the long-term survival in rats with myocardial infarction. Cardiovasc Drugs Ther 22, 479-485.
14. Coort SL, Hasselbaink DM, Koonen DP, Willems J, Coumans WA, Chabowski A, van der Vusse GJ, Bonen A, Glatz JF & Luiken JJ (2004). Enhanced sarcolemmal FAT/CD36 content and triacylglycerol storage in cardiac myocytes from obese Zucker rats. Diabetes 53, 1655-1663.
15. Daniels A, Linz D, van Bilsen M, Rutten H, Sadowski T, Ruf S, Juretschke HP, Neumann-Haefelin C, Munts C, van der Vusse GJ & van Nieuwenhoven FA (2012). Long-term severe diabetes only leads to mild cardiac diastolic dysfunction in Zucker diabetic fatty rats. Eur J Heart Fail 14, 193-201.
16. Daniels A, van Bilsen M, Janssen BJ, Brouns AE, Cleutjens JP, Roemen TH, Schaart G, van der Velden J, van der Vusse GJ & van Nieuwenhoven FA (2010). Impaired cardiac functional reserve in type 2 diabetic db/db mice is associated with metabolic, but not structural, remodelling. Acta Physiol (Oxf) 200, 11-22.
17. Delucchi F, Berni R, Frati C, Cavalli S, Graiani G, Sala R, Chaponnier C, Gabbiani G, Calani L, Del Rio D, Bocchi L, Lagrasta C, Quaini F & Stilli D (2012). Resveratrol treatment reduces cardiac progenitor cell dysfunction and prevents morpho-functional ventricular remodeling in type-1 diabetic rats. PLoS One 7, e39836.
18. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW & Kelly DP (2003). A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A 100, 1226-1231.
19. Fisher-Wellman KH, Mattox TA, Thayne K, Katunga LA, La Favor JD, Neufer PD, Hickner RC, Wingard CJ & Anderson EJ (2013). Novel role for thioredoxin reductase-2 in mitochondrial redox adaptations to obesogenic diet and exercise in heart and skeletal muscle. J Physiol 591, 3471-3486.
20. Guleria RS, Singh AB, Nizamutdinova IT, Souslova T, Mohammad AA, Kendall JA Jr, Baker KM & Pan J (2013). Activation of retinoid receptor-mediated signalling ameliorates diabetes-induced cardiac dysfunction in Zucker diabetic rats. J Mol Cell Cardiol 57, 106-118.
21. Hagler MA, Hadley TM, Zhang H, Mehra K, Roos CM, Schaff HV, Suri RM & Miller JD (2013). TGF-β signalling and reactive oxygen species drive fibrosis and matrix remodelling in myxomatous mitral valves. Cardiovasc Res 99, 175-184.
22. He L, Kim T, Long Q, Liu J, Wang P, Zhou Y, Ding Y, Prasain J, Wood PA & Yang Q (2012). Carnitine palmitoyltransferase-1b deficiency aggravates pressure overload-induced cardiac hypertrophy caused by lipotoxicity. Circulation 126, 1705-1716.
23. Ho CH & Pande SV (1974). On the specificity of the inhibition of adenine nucleotide translocase by long chain acyl-coenzyme A esters. Biochim Biophys Acta 369, 86-94.
24. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P & Auwerx J (2006). Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 127, 1109-1122.
25. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, Ashrafian H, Horowitz J, Fraser AG, Clarke K & Frenneaux M (2005). Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 112, 3280-3288.
26. Lin JF, Lin SM, Chih CL, Nien MW, Su HH, Hu BR, Huang SS & Tsai SK (2008). Resveratrol reduces infarct size and improves ventricular function after myocardial ischemia in rats. Life Sci 83, 313-317.
27. Liu Y, Huang H, Xia W, Tang Y, Li H & Huang C (2010). NADPH oxidase inhibition ameliorates cardiac dysfunction in rabbits with heart failure. Mol Cell Biochem 343, 143-153.
28. Louis XL, Thandapilly SJ, MohanKumar SK, Yu L, Taylor CG, Zahradka P & Netticadan T (2012). Treatment with low-dose resveratrol reverses cardiac impairment in obese prone but not in obese resistant rats. J Nutr Biochem 23, 1163-1169.
29. Marsh SA, Powell PC, Agarwal A, Dell'Italia LJ & Chatham JC (2007). Cardiovascular dysfunction in Zucker obese and Zucker diabetic fatty rats: role of hydronephrosis. Am J Physiol Heart Circ Physiol 293, H292-H298.
30. Mazumder PK, O'Neill BT, Roberts MW, Buchanan J, Yun UJ, Cooksey RC, Boudina S & Abel ED (2004). Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 53, 2366-2374.
31. Neitzel AS, Carley AN & Severson DL (2003). Chylomicron and palmitate metabolism by perfused hearts from diabetic mice. Am J Physiol Endocrinol Metab 284, E357-E365.
32. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I & Brownlee M (2000). Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404, 787-790.
33. Okere IC, Chandler MP, McElfresh TA, Rennison JH, Sharov V, Sabbah HN, Tserng KY, Hoit BD, Ernsberger P, Young ME & Stanley WC (2006). Differential effects of saturated and unsaturated fatty acid diets on cardiomyocyte apoptosis, adipose distribution, and serum leptin. Am J Physiol Heart Circ Physiol 291, H38-H44.
34. Park TS, Hu Y, Noh HL, Drosatos K, Okajima K, Buchanan J, Tuinei J, Homma S, Jiang XC, Abel ED & Goldberg IJ (2008). Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 49, 2101-2112.
35. Perry CG, Kane DA, Herbst EA, Mukai K, Lark DS, Wright DC, Heigenhauser GJ, Neufer PD, Spriet LL & Holloway GP (2012). Mitochondrial creatine kinase activity and phosphate shuttling are acutely regulated by exercise in human skeletal muscle. J Physiol 590, 5475-5486.
36. Perry CG, Kane DA, Lin CT, Kozy R, Cathey BL, Lark DS, Kane CL, Brophy PM, Gavin TP, Anderson EJ & Neufer PD (2011). Inhibiting myosin-ATPase reveals a dynamic range of mitochondrial respiratory control in skeletal muscle. Biochem J 437, 215-222.
37. Qin F, Siwik DA, Luptak I, Hou X, Wang L, Higuchi A, Weisbrod RM, Ouchi N, Tu VH, Calamaras TD, Miller EJ, Verbeuren TJ, Walsh K, Cohen RA & Colucci WS (2012). The polyphenols resveratrol and S17834 prevent the structural and functional sequelae of diet-induced metabolic heart disease in mice. Circulation 125, 1757-1764, S1751-1756.
38. Radovits T, Korkmaz S, Loganathan S, Barnucz E, Bomicke T, Arif R, Karck M & Szabo G (2009). Comparative investigation of the left ventricular pressure-volume relationship in rat models of type 1 and type 2 diabetes mellitus. Am J Physiol Heart Circ Physiol 297, H125-H133.
39. Rimbaud S, Ruiz M, Piquereau J, Mateo P, Fortin D, Veksler V, Garnier A & Ventura-Clapier R (2011). Resveratrol improves survival, hemodynamics and energetics in a rat model of hypertension leading to heart failure. PLoS One 6, e26391.
40. Robich MP, Chu LM, Burgess TA, Feng J, Han Y, Nezafat R, Leber MP, Laham RJ, Manning WJ & Sellke FW (2012). Resveratrol preserves myocardial function and perfusion in remote nonischemic myocardium in a swine model of metabolic syndrome. J Am Coll Surg 215, 681-689.
41. ε-(carboxymethyl) lysine. Eur J Heart Fail 8, 2-6.
42. Schmitz FJ, Rosen P & Reinauer H (1995). Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor Etomoxir. Horm Metab Res 27, 515-522.
43. 2 emission during long-chain fatty acid oxidation. J Biol Chem 285, 5748-5758.
44. Smith BK, Perry CG, Herbst EA, Ritchie IR, Beaudoin MS, Smith JC, Neufer PD, Wright DC & Holloway GP (2013). Submaximal ADP-stimulated respiration is impaired in ZDF rats and recovered by resveratrol. J Physiol 591, 6089-6101.
45. 50 for CPT-I: implications for predicting in vivo fatty acid oxidation rates. Biochem J 448, 13-20.
46. Soufi FG, Vardyani M, Sheervalilou R, Mohammadi M & Somi MH (2012). Long-term treatment with resveratrol attenuates oxidative stress pro-inflammatory mediators and apoptosis in streptozotocin-nicotinamide-induced diabetic rats. Gen Physiol Biophys 31, 431-438.
47. Stanley WC, Lopaschuk GD & McCormack JG (1997). Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 34, 25-33.
48. Stanley WC, Recchia FA & Lopaschuk GD (2005). Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85, 1093-1129.
49. Thirunavukkarasu M, Penumathsa SV, Koneru S, Juhasz B, Zhan L, Otani H, Bagchi D, Das DK & Maulik N (2007). Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med 43, 720-729.
50. Turcani M & Rupp H (1997). Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation 96, 3681-3686.
51. Tuunanen H, Engblom E, Naum A, Nagren K, Hesse B, Airaksinen KE, Nuutila P, Iozzo P, Ukkonen H, Opie LH & Knuuti J (2006). Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 114, 2130-2137.
52. van den Brom CE, Huisman MC, Vlasblom R, Boontje NM, Duijst S, Lubberink M, Molthoff CF, Lammertsma AA, van der Velden J, Boer C, Ouwens DM & Diamant M (2009). Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats: studies using positron emission tomography. Cardiovasc Diabetol 8, 39.
53. Ventura-Clapier R, Garnier A, Veksler V & Joubert F (2011). Bioenergetics of the failing heart. Biochim Biophys Acta 1813, 1360-1372.
54. Wang P, Lloyd SG, Zeng H, Bonen A & Chatham JC (2005). Impact of altered substrate utilization on cardiac function in isolated hearts from Zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol 288, H2102-H2110.
55. 14C-labelled substrates in humans. J Clin Invest 79, 359-366.
56. Woldegiorgis G & Shrago E (1979). The recognition of two specific binding sites of the adenine nucleotide translocase by palmitoyl CoA in bovine heart mitochondria and submitochondrial particles. Biochem Biophys Res Commun 89, 837-844.
57. Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz EP, Merkel M, Bensadoun A, Homma S & Goldberg IJ (2003). Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 111, 419-426.
58. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L & Unger RH (2000). Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 97, 1784-1789.